[{"address1": "815 8th Avenue SW", "address2": "Suite 600", "city": "Calgary", "state": "AB", "zip": "T2P 3P2", "country": "Canada", "phone": "855-426-4246", "website": "https://universalibogaine.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Universal Ibogaine Inc., a life sciences company, develops, acquires, and operates addiction treatment clinics in Canada. It undertakes planned clinical trial for research into the use of ibogaine for addiction treatment. The company is headquartered in Calgary, Canada.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Nicholas Peter Karos", "title": "CEO, Director of Capital Markets & Director", "fiscalYear": 2023, "totalPay": 166181, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Greg J. Leavens C.A., CPA", "age": 59, "title": "CFO & Corporate Secretary", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 121174, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Shayne  Nyquvest", "title": "Co-Founder", "fiscalYear": 2023, "totalPay": 160006, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Cathy  Fernandes", "title": "VP of Marketing & VP of Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.01, "open": 0.0105, "dayLow": 0.0105, "dayHigh": 0.015, "regularMarketPreviousClose": 0.01, "regularMarketOpen": 0.0105, "regularMarketDayLow": 0.0105, "regularMarketDayHigh": 0.015, "beta": 5.147, "volume": 396678, "regularMarketVolume": 396678, "averageVolume": 30565, "averageVolume10days": 194059, "averageDailyVolume10Day": 194059, "bid": 0.012, "ask": 0.015, "marketCap": 4629165, "fiftyTwoWeekLow": 0.0013, "fiftyTwoWeekHigh": 0.0309, "priceToSalesTrailing12Months": 1.984384, "fiftyDayAverage": 0.01168, "twoHundredDayAverage": 0.0107693, "currency": "USD", "enterpriseValue": 6928787, "profitMargins": -0.66933995, "floatShares": 280209090, "sharesOutstanding": 308611008, "heldPercentInsiders": 0.0046, "impliedSharesOutstanding": 313513984, "bookValue": 0.005, "priceToBook": 3.0, "lastFiscalYearEnd": 1690761600, "nextFiscalYearEnd": 1722384000, "mostRecentQuarter": 1714435200, "netIncomeToCommon": -1561435, "trailingEps": -0.01, "enterpriseToRevenue": 2.97, "enterpriseToEbitda": -14.436, "52WeekChange": 1.0833333, "SandP52WeekChange": 0.25625563, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "IBOGF", "underlyingSymbol": "IBOGF", "shortName": "Universal Ibogaine Inc.", "longName": "Universal Ibogaine Inc.", "firstTradeDateEpochUtc": 1646145000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "1ef65637-1cbf-307d-bcc7-be7a0685f14f", "messageBoardId": "finmb_611766625", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.015, "recommendationKey": "none", "totalCash": 470114, "totalCashPerShare": 0.002, "ebitda": -479977, "totalDebt": 2769744, "quickRatio": 0.613, "currentRatio": 0.648, "totalRevenue": 2332797, "debtToEquity": 177.812, "revenuePerShare": 0.011, "returnOnAssets": -0.090909995, "returnOnEquity": -0.8311, "freeCashflow": -372189, "operatingCashflow": -747884, "revenueGrowth": 0.253, "grossMargins": 0.28284, "ebitdaMargins": -0.20575, "operatingMargins": -0.80872, "financialCurrency": "CAD", "trailingPegRatio": null, "__fetch_time": "2025-01-07"}]